Ghrelin treatment of chronic kidney disease: Improvements in lean body mass and cytokine profile

Mark D. DeBoer, Xinxia Zhu, Peter R. Levasseur, Akio Inui, Zhaoyong Hu, Guofeng Han, William E. Mitch, John E. Taylor, Heather A. Halem, Jesse Z. Dong, Rakesh Datta, Michael D. Culler, Daniel Marks

Research output: Contribution to journalArticle

115 Citations (Scopus)

Abstract

Chronic kidney disease (CKD) is associated with an increase in inflammatory cytokines and can result in cachexia with loss of muscle and fat stores. We previously demonstrated the efficacy of treating a model of cancer cachexia with ghrelin and a ghrelin receptor agonist. Currently, we examine a surgical model of CKD in rats, resulting in uremia and decreased accrual of lean body mass. Treatment with ghrelin and two ghrelin receptor agonists (BIM-28125 and BIM-28131) resulted in increased food intake and an improvement in lean body mass accrual that was related in part to a decrease in muscle protein degradation as assessed by muscle levels of the 14-kDa actin fragment resulting from cleaved actomyosin. Additionally, there was a decrease in circulating inflammatory cytokines in nephrectomized animals treated with ghrelin relative to saline treatment. Ghrelin-treated animals also had a decrease in the expression of IL-1 receptor in the brainstem and a decrease in expression of prohormone convertase-2, an enzyme involved in the processing of proopiomelanocortin to the anorexigenic peptide α-MSH. We conclude that ghrelin treatment in uremia results in improved lean mass accrual in part due to suppressed muscle proteolysis and possibly related to antiinflammatory effects.

Original languageEnglish (US)
Pages (from-to)827-835
Number of pages9
JournalEndocrinology
Volume149
Issue number2
DOIs
StatePublished - Feb 2008

Fingerprint

Ghrelin
Chronic Renal Insufficiency
Cytokines
Ghrelin Receptor
Cachexia
Uremia
Muscles
Proteolysis
Proprotein Convertase 2
Melanocyte-Stimulating Hormones
Anatomic Models
Actomyosin
Pro-Opiomelanocortin
Interleukin-1 Receptors
Muscle Proteins
Brain Stem
Actins
Anti-Inflammatory Agents
Eating
Fats

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Ghrelin treatment of chronic kidney disease : Improvements in lean body mass and cytokine profile. / DeBoer, Mark D.; Zhu, Xinxia; Levasseur, Peter R.; Inui, Akio; Hu, Zhaoyong; Han, Guofeng; Mitch, William E.; Taylor, John E.; Halem, Heather A.; Dong, Jesse Z.; Datta, Rakesh; Culler, Michael D.; Marks, Daniel.

In: Endocrinology, Vol. 149, No. 2, 02.2008, p. 827-835.

Research output: Contribution to journalArticle

DeBoer, MD, Zhu, X, Levasseur, PR, Inui, A, Hu, Z, Han, G, Mitch, WE, Taylor, JE, Halem, HA, Dong, JZ, Datta, R, Culler, MD & Marks, D 2008, 'Ghrelin treatment of chronic kidney disease: Improvements in lean body mass and cytokine profile', Endocrinology, vol. 149, no. 2, pp. 827-835. https://doi.org/10.1210/en.2007-1046
DeBoer, Mark D. ; Zhu, Xinxia ; Levasseur, Peter R. ; Inui, Akio ; Hu, Zhaoyong ; Han, Guofeng ; Mitch, William E. ; Taylor, John E. ; Halem, Heather A. ; Dong, Jesse Z. ; Datta, Rakesh ; Culler, Michael D. ; Marks, Daniel. / Ghrelin treatment of chronic kidney disease : Improvements in lean body mass and cytokine profile. In: Endocrinology. 2008 ; Vol. 149, No. 2. pp. 827-835.
@article{461d7500183a4b7fa1bee3f3120723af,
title = "Ghrelin treatment of chronic kidney disease: Improvements in lean body mass and cytokine profile",
abstract = "Chronic kidney disease (CKD) is associated with an increase in inflammatory cytokines and can result in cachexia with loss of muscle and fat stores. We previously demonstrated the efficacy of treating a model of cancer cachexia with ghrelin and a ghrelin receptor agonist. Currently, we examine a surgical model of CKD in rats, resulting in uremia and decreased accrual of lean body mass. Treatment with ghrelin and two ghrelin receptor agonists (BIM-28125 and BIM-28131) resulted in increased food intake and an improvement in lean body mass accrual that was related in part to a decrease in muscle protein degradation as assessed by muscle levels of the 14-kDa actin fragment resulting from cleaved actomyosin. Additionally, there was a decrease in circulating inflammatory cytokines in nephrectomized animals treated with ghrelin relative to saline treatment. Ghrelin-treated animals also had a decrease in the expression of IL-1 receptor in the brainstem and a decrease in expression of prohormone convertase-2, an enzyme involved in the processing of proopiomelanocortin to the anorexigenic peptide α-MSH. We conclude that ghrelin treatment in uremia results in improved lean mass accrual in part due to suppressed muscle proteolysis and possibly related to antiinflammatory effects.",
author = "DeBoer, {Mark D.} and Xinxia Zhu and Levasseur, {Peter R.} and Akio Inui and Zhaoyong Hu and Guofeng Han and Mitch, {William E.} and Taylor, {John E.} and Halem, {Heather A.} and Dong, {Jesse Z.} and Rakesh Datta and Culler, {Michael D.} and Daniel Marks",
year = "2008",
month = "2",
doi = "10.1210/en.2007-1046",
language = "English (US)",
volume = "149",
pages = "827--835",
journal = "Endocrinology",
issn = "0013-7227",
publisher = "The Endocrine Society",
number = "2",

}

TY - JOUR

T1 - Ghrelin treatment of chronic kidney disease

T2 - Improvements in lean body mass and cytokine profile

AU - DeBoer, Mark D.

AU - Zhu, Xinxia

AU - Levasseur, Peter R.

AU - Inui, Akio

AU - Hu, Zhaoyong

AU - Han, Guofeng

AU - Mitch, William E.

AU - Taylor, John E.

AU - Halem, Heather A.

AU - Dong, Jesse Z.

AU - Datta, Rakesh

AU - Culler, Michael D.

AU - Marks, Daniel

PY - 2008/2

Y1 - 2008/2

N2 - Chronic kidney disease (CKD) is associated with an increase in inflammatory cytokines and can result in cachexia with loss of muscle and fat stores. We previously demonstrated the efficacy of treating a model of cancer cachexia with ghrelin and a ghrelin receptor agonist. Currently, we examine a surgical model of CKD in rats, resulting in uremia and decreased accrual of lean body mass. Treatment with ghrelin and two ghrelin receptor agonists (BIM-28125 and BIM-28131) resulted in increased food intake and an improvement in lean body mass accrual that was related in part to a decrease in muscle protein degradation as assessed by muscle levels of the 14-kDa actin fragment resulting from cleaved actomyosin. Additionally, there was a decrease in circulating inflammatory cytokines in nephrectomized animals treated with ghrelin relative to saline treatment. Ghrelin-treated animals also had a decrease in the expression of IL-1 receptor in the brainstem and a decrease in expression of prohormone convertase-2, an enzyme involved in the processing of proopiomelanocortin to the anorexigenic peptide α-MSH. We conclude that ghrelin treatment in uremia results in improved lean mass accrual in part due to suppressed muscle proteolysis and possibly related to antiinflammatory effects.

AB - Chronic kidney disease (CKD) is associated with an increase in inflammatory cytokines and can result in cachexia with loss of muscle and fat stores. We previously demonstrated the efficacy of treating a model of cancer cachexia with ghrelin and a ghrelin receptor agonist. Currently, we examine a surgical model of CKD in rats, resulting in uremia and decreased accrual of lean body mass. Treatment with ghrelin and two ghrelin receptor agonists (BIM-28125 and BIM-28131) resulted in increased food intake and an improvement in lean body mass accrual that was related in part to a decrease in muscle protein degradation as assessed by muscle levels of the 14-kDa actin fragment resulting from cleaved actomyosin. Additionally, there was a decrease in circulating inflammatory cytokines in nephrectomized animals treated with ghrelin relative to saline treatment. Ghrelin-treated animals also had a decrease in the expression of IL-1 receptor in the brainstem and a decrease in expression of prohormone convertase-2, an enzyme involved in the processing of proopiomelanocortin to the anorexigenic peptide α-MSH. We conclude that ghrelin treatment in uremia results in improved lean mass accrual in part due to suppressed muscle proteolysis and possibly related to antiinflammatory effects.

UR - http://www.scopus.com/inward/record.url?scp=38549149911&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38549149911&partnerID=8YFLogxK

U2 - 10.1210/en.2007-1046

DO - 10.1210/en.2007-1046

M3 - Article

C2 - 18039782

AN - SCOPUS:38549149911

VL - 149

SP - 827

EP - 835

JO - Endocrinology

JF - Endocrinology

SN - 0013-7227

IS - 2

ER -